Which has higher earnings and valuation, MDWD or PHAR?

Pharming Group has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 9.26 -$23.88M -$1.80 N/A Pharming Group $376.13M 1.78 $2.85M $0.12 78.67

Does the media favor MDWD or PHAR?

In the previous week, Pharming Group had 1 more articles in the media than MediWound. MarketBeat recorded 4 mentions for Pharming Group and 3 mentions for MediWound. MediWound's average media sentiment score of 0.78 beat Pharming Group's score of 0.42 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, MDWD or MDXG?

MiMedx Group has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 9.26 -$23.88M -$1.80 N/A MiMedx Group $418.63M 1.63 $48.58M $0.04 117.25

Is MDWD or MDXG more profitable?

MiMedx Group has a net margin of 1.76% compared to MediWound's net margin of -170.10%. MiMedx Group's return on equity of 12.09% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -170.10% -47.24% -24.27% MiMedx Group 1.76% 12.09% 9.22%

Is DBVT or MDWD more profitable?

MediWound has a net margin of -170.10% compared to DBV Technologies' net margin of -3,506.53%. MediWound's return on equity of -47.24% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% MediWound -170.10% -47.24% -24.27%

Does the media prefer DBVT or MDWD?

In the previous week, DBV Technologies and DBV Technologies both had 3 articles in the media. MediWound's average media sentiment score of 0.78 beat DBV Technologies' score of 0.04 indicating that MediWound is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral MediWound 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MDWD or STTK more profitable?

Shattuck Labs has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Shattuck Labs' return on equity of -43.57% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -170.10% -47.24% -24.27% Shattuck Labs N/A -43.57% -40.90%

Does the media prefer MDWD or STTK?

In the previous week, Shattuck Labs had 3 more articles in the media than MediWound. MarketBeat recorded 6 mentions for Shattuck Labs and 3 mentions for MediWound. MediWound's average media sentiment score of 0.78 beat Shattuck Labs' score of 0.02 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MDWD or AURA?

In the previous week, MediWound had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for MediWound and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.28 beat MediWound's score of 0.78 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MediWound (MDWD) Competitors

$12.18 -0.04 (-0.33%)

As of 09:55 AM Eastern

Compare

MDWD vs. PHAR, MDXG, DBVT, STTK, and AURA

Should you buy MediWound stock or one of its competitors? MediWound's main competitors and comparable companies include Pharming Group (PHAR), MiMedx Group (MDXG), DBV Technologies (DBVT), Shattuck Labs (STTK), and Aura Biosciences (AURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MediWound compare to Pharming Group?

MediWound (NASDAQ:MDWD) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Pharming Group has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	9.26	-$23.88M	-$1.80	N/A
Pharming Group	$376.13M	1.78	$2.85M	$0.12	78.67

Pharming Group has a net margin of 2.51% compared to MediWound's net margin of -170.10%. Pharming Group's return on equity of 3.40% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Pharming Group	2.51%	3.40%	1.90%

In the previous week, Pharming Group had 1 more articles in the media than MediWound. MarketBeat recorded 4 mentions for Pharming Group and 3 mentions for MediWound. MediWound's average media sentiment score of 0.78 beat Pharming Group's score of 0.42 indicating that MediWound is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

46.8% of MediWound shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MediWound has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

MediWound currently has a consensus price target of $33.00, suggesting a potential upside of 170.05%. Pharming Group has a consensus price target of $38.67, suggesting a potential upside of 309.60%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Pharming Group beats MediWound on 8 of the 15 factors compared between the two stocks.

How does MediWound compare to MiMedx Group?

MediWound (NASDAQ:MDWD) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

MiMedx Group has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	9.26	-$23.88M	-$1.80	N/A
MiMedx Group	$418.63M	1.63	$48.58M	$0.04	117.25

MediWound currently has a consensus price target of $33.00, indicating a potential upside of 170.05%. MiMedx Group has a consensus price target of $8.57, indicating a potential upside of 82.76%. Given MediWound's higher possible upside, research analysts plainly believe MediWound is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, MediWound had 2 more articles in the media than MiMedx Group. MarketBeat recorded 3 mentions for MediWound and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.94 beat MediWound's score of 0.78 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Overall Sentiment
MediWound	Positive
MiMedx Group	Positive

MiMedx Group has a net margin of 1.76% compared to MediWound's net margin of -170.10%. MiMedx Group's return on equity of 12.09% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
MiMedx Group	1.76%	12.09%	9.22%

46.8% of MediWound shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 2.5% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MediWound has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Summary

MiMedx Group beats MediWound on 11 of the 15 factors compared between the two stocks.

How does MediWound compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

DBV Technologies has a beta of -1.04, meaning that its stock price is 204% less volatile than the broader market. Comparatively, MediWound has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

DBV Technologies presently has a consensus price target of $48.50, indicating a potential upside of 437.10%. MediWound has a consensus price target of $33.00, indicating a potential upside of 170.05%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
MediWound	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, DBV Technologies and DBV Technologies both had 3 articles in the media. MediWound's average media sentiment score of 0.78 beat DBV Technologies' score of 0.04 indicating that MediWound is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MediWound has higher revenue and earnings than DBV Technologies. MediWound is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	100.67	-$146.95M	-$3.51	N/A
MediWound	$16.96M	9.26	-$23.88M	-$1.80	N/A

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MediWound has a net margin of -170.10% compared to DBV Technologies' net margin of -3,506.53%. MediWound's return on equity of -47.24% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
MediWound	-170.10%	-47.24%	-24.27%

Summary

MediWound beats DBV Technologies on 9 of the 14 factors compared between the two stocks.

How does MediWound compare to Shattuck Labs?

MediWound (NASDAQ:MDWD) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

MediWound has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	9.26	-$23.88M	-$1.80	N/A
Shattuck Labs	$1M	550.98	-$48.81M	-$0.51	N/A

Shattuck Labs has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Shattuck Labs' return on equity of -43.57% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Shattuck Labs	N/A	-43.57%	-40.90%

46.8% of MediWound shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MediWound currently has a consensus target price of $33.00, indicating a potential upside of 170.05%. Shattuck Labs has a consensus target price of $13.70, indicating a potential upside of 149.54%. Given MediWound's higher probable upside, research analysts clearly believe MediWound is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

MediWound has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

In the previous week, Shattuck Labs had 3 more articles in the media than MediWound. MarketBeat recorded 6 mentions for Shattuck Labs and 3 mentions for MediWound. MediWound's average media sentiment score of 0.78 beat Shattuck Labs' score of 0.02 indicating that MediWound is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Shattuck Labs beats MediWound on 10 of the 16 factors compared between the two stocks.

How does MediWound compare to Aura Biosciences?

MediWound (NASDAQ:MDWD) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

In the previous week, MediWound had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for MediWound and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.28 beat MediWound's score of 0.78 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MediWound has higher revenue and earnings than Aura Biosciences. MediWound is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	9.26	-$23.88M	-$1.80	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Aura Biosciences has a net margin of 0.00% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -47.24% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Aura Biosciences	N/A	-73.18%	-62.00%

MediWound has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

46.8% of MediWound shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MediWound presently has a consensus target price of $33.00, suggesting a potential upside of 170.05%. Aura Biosciences has a consensus target price of $17.50, suggesting a potential upside of 179.11%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

MediWound beats Aura Biosciences on 8 of the 14 factors compared between the two stocks.

Get MediWound News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDWD vs. The Competition

Export

Metric	MediWound	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$156.45M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-6.76	11.31	206.66	19.94
Price / Sales	9.23	1,148.46	562.21	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	3.58	17.08	10.75	6.03
Net Income	-$23.88M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-5.21%	-4.43%	-2.91%	-2.34%
1 Month Performance	-12.25%	-12.48%	-7.38%	-5.31%
1 Year Performance	-34.06%	7.60%	2.96%	-2.94%

MediWound Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDWD MediWound	2.4449 of 5 stars	$12.18 -0.3%	$33.00 +170.9%	-32.9%	$156.45M	$16.96M	N/A	121
PHAR Pharming Group	4.3284 of 5 stars	$9.68 -1.2%	$38.67 +299.4%	-35.4%	$693.62M	$366.48M	80.67	407	News Coverage
MDXG MiMedx Group	3.2949 of 5 stars	$4.62 +1.5%	$8.57 +85.5%	-28.0%	$663.21M	$418.63M	115.53	808	Gap Down
DBVT DBV Technologies	3.5094 of 5 stars	$9.98 -4.4%	$48.50 +386.0%	-45.0%	$656.44M	$5.64M	N/A	161
STTK Shattuck Labs	2.4858 of 5 stars	$5.86 -9.8%	$13.33 +127.5%	+198.4%	$652.36M	$1M	N/A	40	News Coverage Analyst Upgrade Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDWD) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediWound (MDWD) Competitors

MDWD vs. PHAR, MDXG, DBVT, STTK, and AURA

How does MediWound compare to Pharming Group?

Summary

How does MediWound compare to MiMedx Group?

Summary

How does MediWound compare to DBV Technologies?

Summary

How does MediWound compare to Shattuck Labs?

Summary

How does MediWound compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediWound (MDWD) Competitors

MDWD vs. PHAR, MDXG, DBVT, STTK, and AURA

How does MediWound compare to Pharming Group?

Which has higher earnings and valuation, MDWD or PHAR?

Is MDWD or PHAR more profitable?

Does the media favor MDWD or PHAR?

Do institutionals and insiders hold more shares of MDWD or PHAR?

Which has more risk and volatility, MDWD or PHAR?

Do analysts rate MDWD or PHAR?

Summary

How does MediWound compare to MiMedx Group?

Which has higher earnings & valuation, MDWD or MDXG?

Do analysts prefer MDWD or MDXG?

Does the media favor MDWD or MDXG?

Is MDWD or MDXG more profitable?

Do insiders & institutionals believe in MDWD or MDXG?

Which has more risk and volatility, MDWD or MDXG?

Summary

How does MediWound compare to DBV Technologies?

Which has more risk & volatility, DBVT or MDWD?

Do analysts recommend DBVT or MDWD?

Does the media prefer DBVT or MDWD?

Which has higher valuation & earnings, DBVT or MDWD?

Do institutionals and insiders have more ownership in DBVT or MDWD?

Is DBVT or MDWD more profitable?

Summary

How does MediWound compare to Shattuck Labs?

Which has preferable earnings & valuation, MDWD or STTK?

Is MDWD or STTK more profitable?

Do institutionals and insiders have more ownership in MDWD or STTK?

Do analysts rate MDWD or STTK?

Which has more volatility & risk, MDWD or STTK?

Does the media prefer MDWD or STTK?

Summary

How does MediWound compare to Aura Biosciences?

Does the media prefer MDWD or AURA?

Which has stronger earnings & valuation, MDWD or AURA?

Is MDWD or AURA more profitable?

Which has more volatility and risk, MDWD or AURA?

Do institutionals & insiders hold more shares of MDWD or AURA?

Do analysts recommend MDWD or AURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools